AZN's anselamimab fails to meet key goals in late-stage AL amyloidosis trials despite signs of subgroup benefit.

AstraZeneca’s anselamimab has failed to show any benefit in patients with light chain amyloidosis in two Phase III trials. A ...

Summit Therapeutics' HARMONi trial data for ivonescimab showed a clinical benefit but narrowly missed statistical ...

In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a ...

Following a successful patent defense case upheld by China’s IP authority, AstraZeneca invested nearly 9 billion yuan ($1.24 billion) to establish two global R&D centres in Beijing and Shanghai, said ...

Summit Therapeutics surged by 16.05 percent on Wednesday to close at $28.27 apiece, leading the rally of the overall ...

New class of Eureka Fellows selected for their outstanding efforts to build a healthier, more equitable world and will receive support to amplify their sustainability impact in Canada and around ...

In recent years successive governments have sought to close down free speech. If we are to avoid the enslavement of our ...

With the company's market capitalization at Rs 2,292.62 Crore, this dividend payout reflects AstraZeneca's commitment to returning value to its shareholders.

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

AstraZeneca’s CARES phase III clinical programme of anselamimab in light chain amyloidosis fails to meet primary endpoint: Cambridge, UK Thursday, July 17, 2025, 09:00 Hrs [IST] ...

The plan – backed with a £2 billion ($2.68 billion) funding pledge – revolves around three overarching objectives, namely ...